Modality
siRNA
MOA
VEGFi
Target
GIP-R
Pathway
mTOR
MyelofibrosisHNSCC
Development Pipeline
Preclinical
~Sep 2014
→ ~Dec 2015
Phase 1
~Mar 2016
→ ~Jun 2017
Phase 2
Sep 2017
→ Jul 2031
Phase 2Current
NCT08623173
1,598 pts·Myelofibrosis
2017-09→2031-03·Not yet recruiting
NCT05606735
1,609 pts·HNSCC
2020-06→2031-07·Terminated
3,207 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2031-03-165.0y awayPh3 Readout· Myelofibrosis
2031-07-025.3y awayPh3 Readout· HNSCC
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2/3
Not yet…
P2/3
Termina…
Catalysts
Ph3 Readout
2031-03-16 · 5.0y away
Myelofibrosis
Ph3 Readout
2031-07-02 · 5.3y away
HNSCC
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08623173 | Phase 2/3 | Myelofibrosis | Not yet recr... | 1598 | LiverFat |
| NCT05606735 | Phase 2/3 | HNSCC | Terminated | 1609 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| BGN-8936 | BeiGene | Phase 1/2 | FXIa |